African Trypanosomiasis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'African Trypanosomiasis - Pipeline Review, H1 2016', provides an overview of the African Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis - The report reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved African Trypanosomiasis therapeutics and enlists all their major and minor projects - The report assesses African Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for African Trypanosomiasis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 African Trypanosomiasis Overview 6 Therapeutics Development 7 Pipeline Products for African Trypanosomiasis - Overview 7 Pipeline Products for African Trypanosomiasis - Comparative Analysis 8 African Trypanosomiasis - Therapeutics under Development by Companies 9 African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes 10 African Trypanosomiasis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 African Trypanosomiasis - Products under Development by Companies 13 African Trypanosomiasis - Products under Investigation by Universities/Institutes 14 African Trypanosomiasis - Companies Involved in Therapeutics Development 15 Anacor Pharmaceuticals, Inc. 15 Sanofi 16 Scynexis, Inc. 17 African Trypanosomiasis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 24 Drug Profiles 26 AN-4169 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AN-5568 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 DDD-100097 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 fexinidazole - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Peptides for Sleeping Sickness - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecules for African Trypanosomiasis - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules for Malaria and African Trypanosomiasis - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules for Protozoal Infections - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecules for Sleeping Sickness - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 African Trypanosomiasis - Recent Pipeline Updates 39 African Trypanosomiasis - Dormant Projects 40 African Trypanosomiasis - Discontinued Products 41 African Trypanosomiasis - Product Development Milestones 42 Featured News & Press Releases 42 Sep 08, 2015: Clinical trial for first oral drug candidate specifically developed for sleeping sickness 42 Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 42 Jun 28, 2011: Anacor Pharmaceuticals Partnership Advances New Drug Candidate To Combat Sleeping Sickness 43 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46
List of Tables
Number of Products under Development for African Trypanosomiasis, H1 2016 7 Number of Products under Development for African Trypanosomiasis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 African Trypanosomiasis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 15 African Trypanosomiasis - Pipeline by Sanofi, H1 2016 16 African Trypanosomiasis - Pipeline by Scynexis, Inc., H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 25 African Trypanosomiasis Therapeutics - Recent Pipeline Updates, H1 2016 39 African Trypanosomiasis - Dormant Projects, H1 2016 40 African Trypanosomiasis - Discontinued Products, H1 2016 41
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.